Brief: Virpax Pharmaceuticals Inc To Develop Intranasal Cannabidiol Product To Manage Epilepsy In Adults And Children
20/09/2021 14:30
Sept 20 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX TO DEVELOP INTRANASAL CANNABIDIOL PRODUCT FOR THE
MANAGEMENT OF EPILEPSY IN ADULTS AND CHILDREN
* VIRPAX - ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS FROM
NANOMERICS TO
USE NANOMERIC'S MET FOR NASAL DELIVERY OF CBD FOR MANAGEMENT OF
EPILEPSY IN ADULTS, CHILDREN
Source text for Eikon: ID:nBwbHlsyfa
Further company coverage: VRPX.O
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study